Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection

Journal of Pediatrics

Volumn 135, Issue 6, 1999, Pages 675-682

  Viganò, Alessandra ^a,b,c   Dally, Len ^a,b,c   Bricalli, Dorella ^a,b,c   Sala, Natascia ^a,b,c   Pirillo, Maria ^a,b,c   Saresella, Marina ^a,b,c   Trabattoni, Daria ^a,b,c   Vella, Stefano ^a,b,c   Clerici, Mario ^a,b,c   Principi, Nicola ^a,b,c,d  

^a UNIVERSITY OF MILAN   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c Laboratorio di Biologia   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; DIDANOSINE; INDINAVIR; LAMIVUDINE; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; DELAYED HYPERSENSITIVITY; DRUG EFFICACY; DRUG POTENCY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNOPROPHYLAXIS; INCIDENCE; PRIORITY JOURNAL; VERTICAL TRANSMISSION;

EID: 0033504610     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-3476(99)70084-3     Document Type: Article

References (26)

1. 1. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzales C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
2. 2. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Curier JS, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
3. 3. Montaner JSG, Reiss P, Cooper D, Vella S, Harris M, Conway B, et al. A randomized, double-blinded trial comparing combinations of nevirapine, didanosine and zidovudine for HIV infected patients - the INCAS trial. JAMA 1998;279:930-7.
4. 4. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-60.
5. 5. Mouton Y, Alfandari S, Valette M, Cartier F, Dellamonica P, Humbert G, et al. Impact of protease inhibitors on AIDS defining events and hospitalizations in 10 French AIDS reference centres: Federation National des Centres de lutte contre le SIDA. AIDS 1997;11:F101-5.
6. 6. Angel JB. Improvement in cell-mediated immune function, during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir. J Infect Dis 1998;177:808-904.
7. + T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-6.
8. 8. Pontesilli O, Kerkhof-Garde S, Pakker NG, Notermans DW, Roos MTL, Danner SA, et al. Functional lymphocyte reconstitution and HIV-1 specific T cell responses during highly active antiretroviral therapy (HAART). Presented at 12th World AIDS Conference; 1998 June 28-July 3; Geneva, Switzerland; Abstract 31134.
9. 9. Centers for Disease Control and Prevention. Guidelines for the use of antiretroviral agents in pediatric HIV infection. MMWR Morb Mortal Wkly Rep 1998;47(RR-4):1-43.
10. 10. Manfredi R, Monari P, Donzelli C, Furlini G, Re MC, Chiodo F. Protease inhibitors in antiviral therapy of paediatric HIV disease [letter]. Acta Paediatr 1998;87:814-5.
11. 11. Melvin AJ, Mohan KM, Manns Arcuino LA, Edelstein RE, Frenkel LM. Clinical, virologic and immunologic responses of children with advanced human immunodeficiency virus type 1 disease treated with protease inhibitors. Pediatr Infect Dis J 1997;16: 968-76.
12. 12. Kline MW, Fletcher CV, Harris AT, Evans KD, Brundage RC, Remmel RP, et al. A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus. J Pediatr 1998;132: 543-6.
13. 13. Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Morb Mortal Wkly Rep 1994;43(RR-12):1-10.
14. 14. Viganò A, Rombolà G, Barbiano di Belgioioso G, Sala N, Principi N. Subtle occurrence of indinavir-induced acute renal insufficiency. AIDS 1998; 12:954-5.
15. 15. Cohen C, Sun E, Cameron W. Ritonavir-saquinavir combination treatment in HIV-infected patients. Proceedings of 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. 1996 Sept 29-Oct 2; New Orleans, Louisiana. Abstract LB7b.
16. 16. Krogstad P, Wiznia K, Luzuriaga K, Spector SA, Dankner W, Gersten M, et al. Predictors of response to treatment of HIV-1 infected children with the protease inhibitor nelfinavir mesylate. 12th World AIDS Conference; 1998 June 28-July 3; Geneva, Switzerland. Abstract 41191.
17. 17. Mitchla Z, Sharland M, Delmas N, Gibb D. UK experience of Nelfinavir in pediatric HIV-1 infection. 12th World AIDS Conference; 1998 June 28-July 3; Geneva, Switzerland. Abstract 12258.
18. + T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995;332:143-9.
19. 19. Viganò A, Vella S, Principi N, Bricalli D, Sala N, Salvaggio A, et al. Thymus volume correlates with the progression of vertical HIV infection. AIDS 1999; 13:F29-F34.
20. 20. Viganò A, Clerici M, Bricalli D, Saresella M, Difabio S, Principi N, et al. Immune reconstitution and role of thymus during potent antiretroviral therapy in vertically HIV-infected children. 12th World AIDS Conference; 1998 June 28-July 3; Geneva, Switzerland. Abstract 12247.
21. + cell numbers and clinical staging. J Clin Invest 1989;84: 1892-9.
22. + T cell counts. J Infect Dis 1991;164:631-7.
23. 23. Roilides E, Clerici M, DePalma L, Rubin M, Pizzo PA, Shearer G. Helper T-cell responses in children infected with human immunodeficiency virus type 1. J Pediatr 1991;118:724-30.
24. 24. Borleffs JCC, Vrehen HM, Bosboom-Kalsbeek KC, Hoepelman AM, Schuurman HJ, Gmelig-Meyling FHJ. Delayed-type hypersensitivity skin testing in patients with HIV infection. AIDS 1991;5:110-2.
25. 25. Blatt SP, Hendrix CW, Butzin CA. Delayed-type hypersensitivity skin testing predicts progression to AIDS in HIV-infected patients. Ann Intern Med 1993;119:177-84.
26. + T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus. J Infect Dis 1995;172:79-87.